Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the advancement of cell-based therapies to treat individuals suffering from autoimmune disorders. Its primary experimental therapy, KYV-101, an autologous CD19 CAR T-cell candidate, is currently undergoing Phase I clinical evaluation for lupus nephritis and systemic sclerosis, and has progressed to Phase II studies for myasthenia gravis and multiple sclerosis. Furthermore, the company's pipeline includes KYV-201, an allogeneic CD19 CAR T-cell candidate still in preclinical development, designed to address a variety of autoimmune conditions. Kyverna is also exploring therapeutic solutions for other autoimmune diseases, such as inflammatory bowel disease, encompassing Crohn's disease and ulcerative colitis. The firm has established strategic alliances, including a licensing and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product, and a partnership with Kite for programs aimed at treating, diagnosing, and preventing autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. Incorporated in 2018 and headquartered in Emeryville, California, Kyverna Therapeutics, Inc. was formerly known as BAIT Therapeutics, Inc. until its name change in October 2019.
